Quarterly report · Q1

Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥380.3bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥20.7bn2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥31.0bn2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.3bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥24.2bn2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥3.13Tat 2023-03-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.89Tat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥811.5bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.10Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.07Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥423.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥57.7bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥22.8bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥34.6bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.862022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.72022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥42.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥33.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥9.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥13.0bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥11.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥72.7bn
—segment totalrevenue2023-01-01 → 2023-03-31¥458.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥9.7bn
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-03-31¥39.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-03-31¥30.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-03-31¥4.1bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥11.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-03-31−¥235m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥11.3bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥17.3bn
—segment totalrevenue2022-01-01 → 2022-03-31¥389.1bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥380.3bn
—segment totalrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥32.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 706
ItemContextValueUnit
Finance income ope cf IFRSCurrentYTDDuration-3884000000JPY
Finance costs ope cf IFRSPrior1YTDDuration1036000000JPY
Finance costs ope cf IFRSCurrentYTDDuration1421000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-4832000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-14474000000JPY
Decrease increase in trade and other receivables2 ope cf IFRSPrior1YTDDuration37746000000JPY
Decrease increase in trade and other receivables2 ope cf IFRSCurrentYTDDuration38747000000JPY
Increase decrease in trade and other payables2 ope cf IFRSPrior1YTDDuration-24856000000JPY
Increase decrease in trade and other payables2 ope cf IFRSCurrentYTDDuration-27511000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-7038000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-2390000000JPY
Subtotal ope cf IFRSPrior1YTDDuration65379000000JPY
Subtotal ope cf IFRSCurrentYTDDuration88535000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration1687000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration2960000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-666000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-821000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-8701000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-18792000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration57698000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration71882000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration2483000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration165000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-13589000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-20235000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-1477000000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-1739000000JPY
Proceeds from sale of investments inv cf IFRSPrior1YTDDuration3233000000JPY
Proceeds from sale of investments inv cf IFRSCurrentYTDDuration39000000JPY
Purchase of investments inv cf IFRSPrior1YTDDuration-8628000000JPY
Purchase of investments inv cf IFRSCurrentYTDDuration-16102000000JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration-5436000000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration1916000000JPY
Other inv cf IFRSPrior1YTDDuration618000000JPY
Other inv cf IFRSCurrentYTDDuration185000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-22797000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-35771000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-0JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration1205000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration1797000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration1003000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration11000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-4526000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-4136000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-4815000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-5044000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-27428000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-27308000000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration-JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass